Table 1.
Patients’ characteristics, extracted variables, and results of univariate analyses (n = 124).
| Grade 0 (n = 72) | Grade 1 (n = 22) | Grade 2 (n = 25) | Grade 3 (n = 5) | P value | Odds ratio (95%CI) | |
|---|---|---|---|---|---|---|
| Demographic data | ||||||
| Male, n (%) | 36 (50.0) | 10 (45.5) | 14 (56.0) | 3 (60.0) | 0.670 |
1.16 (0.58–2.31) |
| Age (y), median (range) |
66.5 (28–87) |
72 (41–82) |
71 (52–85) |
71 (37–81) |
0.032* |
1.04 (1.00–1.07) |
| Height (cm), median (range) | 162.7 (142.8–178.6) |
156.6 (140.6–183.5) |
162.5 (144–173) |
160.5 (149–171.3) |
0.407 |
0.98 (0.95–1.02) |
| Weight (kg), median (range) |
55.1 (31.1–94.1) |
51.7 (37–103) |
57.7 (42–94) |
45 (30–66.3) |
0.932 |
1.00 (0.97–1.03) |
| BMI (kg/m2), median (range) |
21.0 (12.7–30.7) |
21.8 (14.6–32.7) |
22.2 (15.9–32.5) |
17.8 (13.5–22.6) |
0.606 |
1.02 (0.94–1.11) |
| BSA (m2), median (range) |
1.58 (1.14–2.1) |
1.50 (1.28–2.2) |
1.58 (1.33–2.05) |
1.43 (1.15–1.78) |
0.699 |
0.71 (0.13–4.00) |
| PS (0/1/2) | 31/37/4 | 11/10/1 | 13/12/0 | 3/1/1 | 0.311 |
0.73 (0.4–1.34) |
| Cancer type | ||||||
| Lung, n (%) | 11(15.3) | 5(22.7) | 1(4.0) | 0 | 0.315 |
0.58 (0.20–1.69) |
| Colorectal, n (%) | 34(47.2) | 10(45.5) | 16(64.0) | 5(100.0) | 0.060 |
1.96 (0.97–3.94) |
| Gastric, n (%) | 14(19.4) | 4(18.2) | 3(12.0) | 0 | 0.291 |
0.59 (0.22–1.57) |
| Breast, n (%) | 13(18.1) | 3(13.6) | 5(20.0) | 0 | 0.694 |
0.83 (0.33–2.11) |
| Comorbidity | ||||||
| Hypertension, n (%) | 21(29.2) | 10(45.5) | 13(52.0) | 2(40.0) | 0.037* |
2.12 (1.05–4.30) |
| Diabetes mellitus, n (%) | 12(16.7) | 3(13.6) | 9(36.0) | 1(20.0) | 0.126 |
1.91 (0.83–4.36) |
| Laboratory test value | ||||||
| Serum creatinine, mg/dL, median (range) |
0.69 (0.38–1.12) |
0.67 (0.47–1.13) |
0.73 (0.37–1.32) |
0.50 (0.38–1.77) |
0.015* |
7.55 (1.49–38.3) |
| Creatinine clearance, mL/min, median (range) |
78.4 (29.5–148.0) |
70.5 (40.0–131.1) |
69.0 (36.6–161.2) |
80.4 (19.2–163.9) |
0.152 |
0.99 (0.98–1.00) |
| Albumin, g/dL, median (range) |
3.9 (2.3–4.7) |
3.8 (2.7–4.5) |
3.9 (3.1–4.6) |
3.3 (2.9–4.1) |
0.83 |
0.93 (0.46–1.85) |
| LDH, U/L, median (range) |
229 (139–1528) |
218 (158–558) |
218 (146–366) |
173 (162–194) |
0.134 |
0.997 (0.994–1.001) |
| Fibrinogen, mg/dL, median (range), n = 84 |
347 (114–597) n = 51 |
370 (212–873) n = 16 |
390 (235–650) n = 13 |
446.5 (363–489) n = 4 |
0.019* |
1.004 (1.001–1.008) |
| Angiogenesis inhibitor | ||||||
| Bevacizumab, n (%) | 44(61.1) | 10(45.5) | 18(72.0) | 3(60.0) | 0.796 |
1.10 (0.54–2.22) |
| Ramucirumab, n (%) | 26(36.1) | 10(45.5) | 5(20.0) | 2(40.0) | 0.469 |
0.76 (0.37–1.59) |
| Aflibercept, n (%) | 2(2.8) | 2(9.1) | 2(8.0) | 0 | 0.365 |
2.01 (0.44–9.13) |
| Bevacizumab dose, mg/kg, mean ± SD | 8.17 ± 2.98 | 8.75 ± 3.95 | 7.64 ± 2.77 | 8.33 ± 5.77 | 0.754 |
0.98 (0.85–1.13) |
| Ramucirumab dose, mg/kg, mean ± SD | 8.5 ± 0 | 8.6 ± 0 | 8 ± 0.57 | 8 ± 0 | 0.341 |
0.69 (0.32–1.48) |
| Aflibercept dose, mg/kg, mean ± SD | 4 ± 0 | 4 ± 0 | 3.6 ± 0.57 | - | 0.998 | - |
| Number of cycles |
8 (2–52) |
9 (2–33) |
17 (2–72) |
13 (3–45) |
0.003* |
1.04 (1.02–1.07) |
| Regimen | ||||||
| Platinum-containing, n (%) | 3(4.2) | 1(4.5) | 0 | 1(20.0) | 0.969 |
1.04 (0.18–5.87) |
| Taxane-containing, n (%) | 32 (44.4) | 10 (45.5) | 7(28.0) | 1(20.0) | 0.155 |
0.59 (0.29–1.22) |
| Fluorouracil-containing, n (%) | 34 (47.2) | 10(45.5) | 16 (64.0) | 4 (80.0) | 0.121 |
1.73 (0.87–3.47) |
| Concomitant medication | ||||||
| RAS inhibitors, n (%) | 9(12.5) | 4(18.2) | 7(28.0) | 1(20.0) | 0.010* |
2.09 (0.87–5.04) |
| Calcium channel blockers, n (%) | 11(15.3) | 7(31.8) | 11(44.0) | 2(40.0) | 0.003* |
3.27 (1.5–7.1) |
| Loop or thiazide diuretics, n (%) | 6(8.3) | 1(4.5) | 1(4.0) | 1(20.0) | 0.713 |
0.77 (0.2–3.04) |
| Vital signs before administration | ||||||
| SBP, mmHg, median (range) |
123 (89–151) |
123 (98–156) |
131 (100–177) |
135 (124–152) |
0.003* |
1.04 (1.01–1.06) |
| DBP, mmHg, median (range) |
73 (43–97) |
73.5 (60–106) |
73.5 (47–98) |
79 (67–82) |
0.238 |
1.02 (0.99–1.05) |
CI, confidence interval; BMI, body mass index; BSA, body surface area; PS, Performance Status; RAS, renin-angiotensin system; SBP, systolic blood pressure; DBP, diastolic blood pressure.
*P < 0.05.